Tests HSK44459 pill in adults with moderate to severe plaque psoriasis
Tests an oral drug, HSK44459, against placebo in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 2
Where in China
- Hangzhou First People's HospitalHangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Haisco Pharmaceutical Group Co., Ltd.
- Trial code
- NCT07150988
- Record updated
- 2 September 2025
- Original description
The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.Read full original descriptionShow less
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.
Inclusion: Fully understand and voluntarily participate this trial, and sign the informed consent form; Age≥18 years, regardless of gender; Plaque psoriasis; A candidate for systemic therapy; Agree to use a highly effective method(s) of from the signing of the informed consent form to 3 months post-treatment.
Exclusion: Can not discontinue the prohibited medications specified in the protocol before the first dose and throughout the entire study period; Has undergone or plans to undergo major surgery; Presence of other dermatological or autoimmune diseases; Presence of active infection requiring systemic therapy; History of cardiovascular or cerebrovascular diseases; History of suicide attempts or major psychiatric disorders; History of malignant tumors; History of gastrointestinal surgery or diseases that may have impact on the study; History of drug abuse, illicit drug use, or alcohol abuse; History of severe drug allergies; Laboratory abnormalities with clinical significance; Forms of psoriasis other than chronic plaque-type; Pregnant or lactating women; Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.